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Multiplexing PKA and ERK1&2 
kinases FRET biosensors in living 
cells using single excitation 
wavelength dual colour FLIM
Claire Demeautis1,2, François Sipieter3,4,5, Julien Roul1,2,†, Catherine Chapuis1,2, 
Sergi Padilla-Parra6,7, Franck B. Riquet3,4,8 & Marc Tramier1,2,9
Monitoring of different signalling enzymes in a single assay using multiplex biosensing provides a 
multidimensional workspace to elucidate biological processes, signalling pathway crosstalk, and 
determine precise sequence of events at the single living cell level. In this study, we interrogate the 
complexity in cAMP/PKA-MAPK/ERK1&2 crosstalk by using multi-parameter biosensing experiments 
to correlate biochemical activities simultaneously in time and space. Using a single excitation 
wavelength dual colour FLIM method we are able to detect fluorescence lifetime images of two 
donors to simultaneously measure PKA and ERK1&2 kinase activities in the same cellular localization 
by using FRET biosensors. To this end, we excite two FRET donors mTFP1 and LSSmOrange with 
a 440 nm wavelength and we alleviate spectral bleed-through associated limitations with the very 
dim-fluorescent acceptor ShadowG for mTFP1 and the red-shifted mKate2 for LSSmOrange. The 
simultaneous recording of PKA and ERK1&2 kinase activities reveals concomitant EGF-mediated 
activations of both kinases in HeLa cells. Under these conditions the subsequent Forskolin-induced 
cAMP release reverses the transient increase of EGF-mediated ERK1&2 kinase activity while reinforcing 
PKA activation. Here we propose a validated methodology for multiparametric kinase biosensing in 
living cells using FRET-FLIM.
External signals are integrated at the cellular level through a cascade of events that amplifies and transmits the 
incoming signal towards a specific outcome1. To regulate intensity, duration and specificity of the response, a 
cell relies on several interconnected signal transduction pathways2. This phenomenon, referred to as crosstalk, is 
defined by the orchestrated action of effector molecules to elicit a specific cellular response3. A typical example of 
signalling pathways crosstalk is that of cyclic adenosine monophosphate/protein kinase-A (cAMP/PKA) with the 
mitogen-activated protein kinase/extracellular signal-regulated kinase 1&2 (MAPK/ERK1&2)4.
The serine/threonine kinase ERK, one member of the MAPK family, propagates a variety of cellular activi-
ties depending on its spatiotemporal activation state. The MAPK cascade is composed of three-layers of kinases 
acting as a signalling relay: a MAPK kinase kinase (Raf), a MAPK kinase (MEK) and a MAPK (ERK)5. Another 
layer of regulation of the pathway involves scaffold proteins as well as positive and negative feedbacks to control 
the duration, the magnitude and subcellular compartmentalization of ERK activity6–8. PKA is a serine/threonine 
kinase that forms a tetramer in its inactive state containing two regulatory (R) and two catalytic (C) units. Upon 
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binding of cAMP to the two regulatory subunits, the two catalytic subunits dissociate from the holoenzyme 
and then become active9. Once activated, both PKA and ERK1&2 translocate into the nucleus to phosphorylate 
numerous downstream substrates. Although first described more than 20 years ago and well documented since, it 
is still intensively studied, as there are still some conflicting results and unresolved issues10,11. In fact, combinato-
rial possibilities, expression patterns, activity profiles and spatiotemporal regulation of cell- and situation- specific 
effector molecules are complicating the analyses of dynamic signalling networks.
The best-characterized connections are PKA-dependent ERK activity modulation mediated by different Raf 
isoforms in different cell types11. These differential effects are explained by the fact that Raf kinase family com-
prises different isoforms. These carry out non-redundant functions, are not ubiquitously found in all tissue, and 
can be expressed at different levels12,13. PKA scaffold proteins such as the A-kinase anchoring proteins (AKAP) 
together with that of ERK1&2, the kinase suppressor of Ras (KSR), can enhance cAMP control of the ERK1/2 
cascade14,15 regulating PKA and ERK1&2 activation as well as phosphodiesterases (PDE) by controlling intracel-
lular cAMP levels14,16. Another connection is found at the level of PDEs, which terminate cAMP signalling by 
hydrolysing cAMP. PDEs that are directly targeted by ERK1&217 were recently found to bind to and to regulate 
Raf-1 kinase18.
Such a level of complexity in cAMP/PKA-MAPK/ERK1&2 crosstalk calls for novel approaches. Genetically 
encoded Förster Resonance Energy Transfer (FRET) biosensors are powerful tools for monitoring spatiotempo-
ral biochemical activities in living samples19. The main advantage of these tools is to monitor the amplitude, the 
duration and the localization of a biochemical activity during time-lapse fluorescence microscopy acquisition in 
living samples. Multi-parameter biosensing experiments have become essential to correlate biochemical activities 
during a dedicated cellular process. A very exciting challenge has thus been to follow several FRET biosensors in 
the same sample at the same time and location20–24. Although simultaneous recording of multiple cellular events 
was managed, the multiplex FRET biosensors approaches suffer from two limitations: (i) a spectral bleed-through 
of the first acceptor in the second donor emission band dependent on biosensors concentration, and (ii) the 
multiple excitation wavelengths necessitate sequential acquisitions that are not optimal for simultaneous obser-
vation of several biosensors. Here, we report on a method dealing with these different limitations for multiplexing 
genetically encoded FRET biosensors. We reasoned that single excitation wavelength combined with FRET-FLIM 
measurements could overcome such limitations. Taking advantage of the long stoke shift of Large Stoke Shift 
mOrange (LSSmOrange)25, we used a 440 nm single excitation wavelength for both donors, monomeric teal 
fluorescent protein (mTFP1) and LSSmOrange, and a dual colour fluorescence lifetime imaging microscopy 
(FLIM) to simultaneously measure signals from two genetically encoded FRET biosensors. We took advantage 
of dim-fluorescent acceptors; a yellow fluorescent protein (YFP)-based resonance energy accepting chromopro-
tein (sREACh) and its blue shift spectrum mutant (ShadowG)26 for mTFP1, and the red-shifted mKate227 for 
LSSmOrange. Because ShadowG is darker than sREACh26 (which is one hundred fold less fluorescent than YFP) 
the spectral bleed-through between the two biosensors was reduced. We validated our approach by applying this 
methodology to simultaneously monitor, for the first time, two kinase activities at the same cellular location. 
MAPK/ERK1&2 and cAMP/PKA interplay in living HeLa cells was examined using EKAR2G28 and AKAR429 
biosensors respectively modified with mTFP1/ShadowG and LSSmOrange/mKate2 fluorescent protein pairs. We 
could report on EGF-mediated ERK1&2 and PKA activation in HeLa cells. The relevance of our methodology was 
clearly illustrated upon Forskolin-mediated increase in cAMP levels following EGF stimulation. Using these con-
ditions we could simultaneously record cAMP inhibitory effect on EGF-mediated ERK1&2 activity level together 
with its reinforcing of PKA activity.
Results
LSSmOrange is an appropriate FRET donor for mKate2 and can be simultaneously used with 
mTFP1 in single excitation wavelength dual colour FLIM. To complement a conventional cyan FRET 
donor, we first searched for a second FRET donor that could also be excited at 440 nm but with a red-shifted emis-
sion spectrum to accommodate simultaneous acquisition of the two donors. We used Large Stoke Shift mOrange 
(LSSmOrange) that is excited at 440 nm and emits in the orange at 572 nm25. To validate our choice, we needed to 
determine whether LSSmOrange was suitable for FRET-FLIM experiments. Fluorescence decay measurements 
in U2OS cells expressing LSSmOrange were performed by TCSPC. LSSmOrange fluorescence decay can be best 
fitted with a single exponential model, with a measured lifetime of 2.75 ± 0.07 ns (Fig. 1A).
While mKate2 was already successfully used as an acceptor for LSSmOrange for intensity-based FRET studies25, 
we verified that this is also the case for FRET-FLIM. LSSmOrange and LSSmOrange-mKate2 tandem plasmids 
were transfected in U2OS cells and cells were subjected to FRET-FLIM measurements using both (TCSPC) and 
time gated FLIM systems30. LSSmOrange-mKate2 tandem showed a faster decay as compared to LSSmOrange 
alone (Fig. 1A). This difference in fluorescence decay indicates that mKate2 is an appropriate acceptor for 
LSSmOrange for FRET-FLIM studies. By using a bi-exponential model, we were able to quantify this decay with 
a FRET lifetime of 1.18 ± 0.12 ns and a fraction of donor exhibiting FRET (fD) of 0.54 ± 0.02. These values are 
similar to other validated FRET pairs for FLIM such as Enhanced Green Fluorescent Protein (EGFP)/mCherry 
(fD = 0.51) and mTFP1/EYFP (fD = 0.73) with the same TCSPC method31.
Next, using the dual colour fastFLIM system combining the fastFLIM prototype30 and a dual view system (see 
Methods for details), we confirmed that LSSmOrange fluorescence emission was only recorded in the orange 
channel and not in the blue channel (Fig. 1B). In cells expressing the donor alone, we measured a mean fluores-
cence lifetime for LSSmOrange of 2.76 ± 0.03 ns (Fig. 1B). However, when expressed in tandem with mKate2 we 
measured a decreased mean lifetime of 2.32 ± 0.08 ns (Fig. 1B), corresponding to a mean FRET efficiency of 0.16 
(calculated using: pseudoE = 1 − < τ > /< τ > D where < τ > D relates to the lifetime of the donor alone31). Again 
here, quantitative comparison of LSSmOrange/mKate2 pair with the two other FRET pairs characterized for 
FRET-FLIM indicated an intermediate FRET efficiency higher for the EGFP/mCherry FRET pair (mean FRET 
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efficiency of 0.09), but still lower for the mTFP1/EYFP FRET pair (mean FRET efficiency of 0.23)31. mTFP132 used 
in the aforementioned study is an appropriate cyan donor for FRET by FLIM31.
Combining single excitation wavelength at 440 nm with the cyan and orange channels of the dual colour 
FLIM set up, we measured mTFP1 and LSSmOrange fluorescence lifetimes expressed either alone or together in 
the same U2OS cells (Supplementary Figure S1). When expressed alone most of mTFP1 fluorescence emission 
was recovered in cyan channel. However, due to the large emission spectrum of mTFP1 (from 475 nm to 525 nm 
at half maximum), spectral bleed-through was detectable in the orange channel. It is noteworthy that mTFP1 
fluorescence intensity levels were insufficient to determine a fluorescence lifetime in this channel. An average 
fluorescence lifetime of 2.62 ± 0.03 ns for mTFP1 was measured in the cyan channel. When LSSmOrange was 
expressed alone, as expected no signal was detectable in cyan channel and LSSmOrange average fluorescence 
lifetime measured in the orange channel was 2.76 ± 0.03 ns. When both fluorescent proteins were co-expressed 
in U2OS cells, average fluorescence lifetimes were 2.62 ± 0.03 ns for mTFP1 and 2.76 ± 0.04 ns for LSSmOrange, 
in the cyan and the orange channel respectively. In spite of the few photons coming from the mTFP1 spectral 
bleed-through in the orange channel, the LSSmOrange lifetime determination was unaffected. Our results indi-
cate that these fluorescent proteins can be simultaneously used as donors in single wavelength excitation dual 
colour FLIM experiments.
ShadowG is an efficient dim-fluorescent FRET acceptor for mTFP1 to reduce acceptor spectral 
bleed-through in LSSmOrange channel when using dual colour FLIM. Next, we co-expressed 
mTFP1-EYFP and LSSmOrange-mKate2 tandems in U2OS cell to determine whether both FRET accep-
tors, EYFP and mKate2, would be suitable with the single excitation wavelength dual colour FLIM approach 
(Supplementary Figure S2). Since the lifetime of a fluorophore is independent from the concentration, mTFP1 
fluorescence lifetime was unaffected by the fluorescence intensity level and thus the amount of mTFP1 con-
struct expressed in the cell. As expected, mTFP1 fluorescence lifetimes were unaffected by mTFP1-EYFP tandem 
expression levels (Supplementary Figure S2, cyan channel, lifetime images). Conversely, a striking increase of 
350 ps in LSSmOrange fluorescence lifetime was calculated depending on mTFP1-EYFP fluorescence intensity 
(Supplementary Figure S2). While the mTFP1 spectral bleed-through did not affect the LSSmOrange fluorescence 
lifetime (Supplementary Figure S1), the spectral bleed-through of EYFP in the LSSmOrange donor channel con-
tributed to LSSmOrange fluorescence lifetime heterogeneity.
To overcome this problem, we took advantage of dim-fluorescent (“dark”) acceptors recently developed for 
FRET analysis26,33. In FLIM, FRET is quantified by shortening of donor fluorescence lifetime, which requires an 
acceptor with a high molar absorption coefficient. However, for intramolecular FLIM-FRET measurements, the 
Figure 1. LSSmOrange has a mono-exponential decay and forms with mKate2 an effective FRET 
pair. (A) Representative LSSmOrange fluorescence lifetime decay profiles measured by TCSPC in U2OS cells 
expressing either LSSmOrange or LSSmOrange-mKate2 tandem constructs. The LSSmOrange-mKate2 decay has 
a shorter slope than that of LSSmOrange. LSSmOrange shows a mono-exponential decay while LSSmOrange-
mKate2 tandem harbors a bi-exponential decay. LSSmOrange alone: τ = 2.75 ± 0.07 ns (n = 11) from mono-
exponential fit; LSSmOrange-mKate2 tandem: τ 1 = 2.80 ns (fixed), τ 2 = 1.18 ± 0.12 ns and a2/a1 + a2 = 0.54 ± 0.02 
(n = 12). (B) Representative intensity and fluorescence lifetime images of either LSSmOrange or LSSmOrange-
mKate2 tandem, expressed in U2OS cells, acquired with the fastFLIM system. The orange channel provides 
either intensity or fluorescence lifetimes: for LSSmOrange: τ LSSmOrange = 2.76 ± 0.03 ns (n = 34) and LSSmOrange-
mKate2: τ LSSmOrange-mKate2 = 2.32 ± 0.08 ns (n = 56). Note that LSSmOrange fluorescence intensity was only 
detectable in the orange channel. Fluorescence lifetimes were calculated as a mean ± SD. (n) indicates number of 
cells from at least 3 independent experiments. Scale bar = 10 μ m.
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brightness of the acceptor is not relevant. Thus, we swapped the EYFP acceptor in our tandems with two different 
dim-acceptors: sREACh33, a EYFP mutant, excited at 514 nm or ShadowG26, a sREACh mutant with a blue shift 
spectrum. ShadowG, which is excited at 470 nm (same excitation spectrum as EGFP), is 114 fold dimmer than 
EYFP and 18 fold dimmer than sREACh. Comparing the fluorescence lifetime of mTFP1-EYFP, mTFP1-sREACh 
and mTFP1-ShadowG tandems with that of mTFP1 alone measured in U2OS cells indicated that sREACh and 
ShadowG are also reliable acceptors for mTFP1 (Supplementary Figure S3). This was further confirmed by mean 
FRET efficiency values of 0.23, 0.22 and 0.18, for mTFP1-EYFP, mTFP1-sREACh and mTFP1-ShadowG tandems, 
respectively. Even if little amounts of spectral bleed-through were detected for all conditions (Supplementary 
Figure S3: second row of fluorescence intensity images), mTFP1-ShadowG turned out to be a good FRET-FLIM 
pair to be combined with LSSmOrange/mKate2 (Supplementary Figure S3: second row of fluorescence lifetime 
images), as we found similar bleed-through levels comparable to mTFP1 alone (Supplementary Figures S1 and S3).
To further investigate the bleed-through effect in our dual FLIM set up, LSSmOrange-mKate2 fluorescence 
lifetime and potential associated spectral bleed-through signals in the orange channel were measured in cells 
spanning mTFP1-Yellow fluorescence expression with blue to orange intensity ratio ranging from 0.4 to 4.4 
(Fig. 2). In the presence of mTFP1-EYFP, LSSmOrange-mKate2 fluorescence lifetime increased from 2.47 ns to 
2.82 ns (Fig. 2, crosses), representative images are shown in Supplementary Figure S2. A decrease in the aver-
age lifetime from 2.27 ns to 2.15 ns was observed in the presence of mTFP1-sREACh (Fig. 2, triangle). Albeit 
slight, LSSmOrange-mKate2 fluorescence lifetime did decrease for intensity ratio values spanning 0.81 up to 3.67 
as represented by the linear regression. Even if spectral bleed-through of sREACh was very dim, the reported 
short sREACh fluorescence lifetime (τ sREACh = 0.32 ns) could provide an explanation33 for this small decrease in 
lifetime. Finally, in presence of mTFP1-ShadowG (Fig. 2, squares), LSSmOrange-mKate2 fluorescence lifetimes 
measured in the orange channel were stable, 2.21 ± 0.02 ns (n = 40), across all intensity ratios tested ranging from 
1.09 to 4.07. Here, we can conclude that mTFP1-Yellow spectral bleed-through contribution to LSSmOrange 
fluorescence lifetime in the orange channel is extremely low with ShadowG, as compared to EYFP or sREACh.
To summarize, we have shown that LSSmOrange exhibits mono-exponential fluorescence decay and that mKate2 
is a reliable acceptor for LSSmOrange. In single excitation dual colour FLIM-FRET measurements, LSSmOrange fluo-
rescence lifetime was not affected by mTFP1 spectral bleed-through in the orange channel. More importantly, the use 
of ShadowG as an acceptor for mTFP1 allows for consistent LSSmOrange fluorescence lifetime determination. Taken 
together, we validated the LSSmOrange/mKate2 and mTFP1/ShadowG FRET pairs as best candidates for our single 
excitation wavelength dual colour FLIM methodology towards multiplexing genetically encoded FRET biosensors.
AKARdual and EKARdual validation for single excitation wavelength dual colour FLIM report on 
EGF-mediated PKA activation in HeLa cells. As a proof of feasibility, we applied our approach to the 
simultaneous monitoring of two kinases, PKA and ERK1&2. Two main reasons motivated our choice. From the 
biological point of view, the interplay between cAMP/PKA and MAPK/ERK1&2 signalling pathways has long 
been established (for review11). Both cascades modulate common cellular processes, and multiple levels of cross-
talk depending on the cellular type and the cellular context have been described10,11,15,34,35. Because ERK1&2 is one 
of the cAMP targets associated with cell proliferation, emphasis has been put on hormone-mediated cAMP/PKA 
Figure 2. Using mTFP1-ShadowG FRET pair results in consistent LSSmOrange-mKate2 fluorescence 
lifetime determination by dual colour FLIM. Graphical representation of LSSmOrange-mKate2 lifetimes 
in the presence of mTFP1-EYFP, mTFP1-sREACh, or mTFP1-ShadowG plotted as a function of cyan/orange 
channel intensity ratio. U2OS cells were co-transfected with a fixed amount of LSSmOrange-mKate2 plasmid 
(0.5 μ g/well) and increasing amounts of mTFP1-YFP, mTFP1-sREACh or mTFP1-ShadowG plasmids (0.25, 
0.5, 075 or 1 μ g/well). Each point corresponds to one cell. In the presence of mTFP1-EYFP (crosses, n = 42), 
LSSmOrange-mKate2 lifetime was markedly increased (τ LSSmOrange-mKate2 = 2,47 ns and 2,82 ns at intensity 
ratio of 0.4 up to 2.67, respectively). In presence of mTFP1-sREACh (triangle n = 47), LSSmOrange-mKate2 
lifetime was decreased (τ LSSmOrange-mKate2 = 2,27 ns and 2,15 ns at intensity ratio of 0.81 up to 3.67, respectively). 
In the presence of mTFP1-ShadowG (squares n = 40), LSSmOrange-mKate2 lifetime remained stable  
(τ LSSmOrange-mKate2 = 2.21 ± 0.02 ns at intensity ratio of 1.09 up to 4.07).
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effect on ERK1&2 activation. So, until recently35, the Growth Factor (GF)-induced PKA activation effect has been 
less studied. From a biotechnological standpoint, we know from our own work36 and that of others28,37 that mod-
ifying FRET pairs has an impact on the performance of KARs. Fortunately, both AKAR29,38,39 and EKAR28,37,40,41 
have already passed various rounds of optimization, which steadily increased their respective performance28,29. 
Accordingly, we anticipated that changing fluorescent proteins on biosensors would not have a major impact on 
the kinase activity of our biosensors.
We generated new versions of EKAR2G28 and AKAR429, named EKARdual and AKARdual (Fig. 3A), that encode 
the FRET pairs mTFP1/ShadowG and LSSmOrange/mKate2, respectively. Standard biosensing reference experi-
ments were carried out in HeLa cells expressing either AKARdual or EKARdual using the dual colour-FLIM system. 
To verify biosensor appropriate behaviour and sensitivity, we first recorded single kinase activity profiles upon ded-
icated activation and subsequent inhibition of either cAMP/PKA or ERK1/2 signalling pathways (Supplementary 
Figure S4). Forskolin/IBMX or EGF treatment resulted in a mean AKARdual and EKARdual fluorescence lifetime 
decrease characteristic of PKA and ERK1/2 pathway activation, which could be inhibited by either H89 or U0126, 
respectively. We could conclude from this first characterization step that AKARdual and EKARdual both exhibited 
the typical behaviour of the respective original biosensors28,29. To control the basal levels of activation for the two 
biosensors in our experimental condition, we have performed inhibitory treatments (U0126 and H89) for cells 
co-expressing AKARdual and EKARdual (Supplementary Figure S5). This supports the conclusion that the resting Hela 
cells show mild activation, as expected in an equilibrium in a biological system between kinases and phosphatases.
To confirm that the spectral bleed-through had no impact on PKA kinase activity measurements, we cross-
checked ERK1&2 and PKA kinase activity profiles by applying dedicated biosensing reference experiments to 
each. HeLa cells transfected with both AKARdual and EKARdual were subjected to either forskolin/H89 or to EGF/
U0126 treatment, and both PKA and ERK1&2 kinase activity profiles were recorded by single excitation wave-
length dual colour FLIM (Fig. 3). We use a 3D representation for Δ Lifetime images to enhance the visualization 
of kinase activity variations. As expected, the cAMP-mediated PKA activation induced by forskolin resulted in a 
decrease of AKARdual fluorescence lifetime (Δ Lifetime of − 40 ± 5 ps at t = 20 min), while having a non-significant 
decrease on ERK1&2 activity (Δ Lifetime of − 13 ± 5 ps at t = 20 min). H89-mediated PKA inhibition counter-
acted the recorded PKA activation by an increase in AKARdual fluorescence lifetime back to the basal activity level 
(Δ Lifetime of − 12 ± 10 ps at t = 60 min) (Fig. 3B and C). When monitoring ERK1&2 and PKA kinase activities 
upon EGF/U0126 treatment (Fig. 3D and E), EKARdual presented its characteristic behaviour. First a decrease 
and then an increase of EKARdual fluorescence lifetime were measured upon EGF (Δ Lifetime of − 59 ± 5 ps at 
t = 20 min) and subsequent U0126 treatment (Δ Lifetime of − 7 ± 11 ps at t = 60 min), respectively. Interestingly, 
an increase of PKA activity was also recorded in response to EGF, as witnessed by the marked decrease of fluo-
rescence lifetime for AKARdual (Δ Lifetime of − 49 ± 4 ps at t = 20 min), which was not significantly affected by 
U0126 treatment (Δ Lifetime of − 34 ± 10 ps at t = 60 min). Note that the FLIM prototype exhibits a lifetime noise 
of ± 20 ps (standard deviation). Any variation within the scale of this noise cannot be considered as a significant 
variation. For example the slight fluctuation in lifetime in Fig. 3E before EGF treatment cannot be attributed any 
meaningful biological relevance since it is within the measured noise range of the microscope system. We have 
simultaneously verified that no photobleaching occurs during lifetime acquisition by monitoring the intensity of 
the first time-gated image (Fig. 3C and E, bottom). Surprisingly, noise fluctuations are correlated for EKARdual 
(cyan channel) and for AKARdual (orange channel), for instance at t = 34 min in Fig. 3C. But this correlation 
does not come from spectral bleed-through as generally observed in conventional ratiometric measurements. 
Here we use the same excitation wavelength and the same time-gated image detection using the dual-view. 
Detection noise is then naturally correlated. Finally, to be convinced that the potential spectral bleed-through 
had no impact on our measurements, we performed experiments in which lifetime variation occurs for the cyan 
species while no variation will be expected in the orange channel. To do so, we have co-expressed EKARdual with 
LSSmOrange or the tandem LSSmOrange-mKate2 in Hela cells and we have performed ERK activation experi-
ment (Supplementary Figure S6). We show that the variations of EKARdual lifetime consecutive of EGF activation 
and U0126 inhibition do not have any impact on LSSmOrange or LSSmOrange-mKate2 lifetimes in the orange 
channel, demonstrating that the potential contributions of cyan species in the orange channel are not detectable 
whatever the measured lifetime from 2.76 ns (LSSmOrange) to 2.32 ns (tandem LSSmOrange-mKate2).
The previous section presents two interesting results in our cellular model: (i) FSK treatment does not acti-
vate ERK and (ii) EGF treatment activates PKA shown in an earlier report where an EGF-mediated PKA activity 
increases in mammalian cells42,43. First, using the new version of EKAR sensor (eCFP/YPet, unpublished opti-
mized version) and ratiometric FRET measurements, we provided evidence that FSK does not activate ERK in 
Hela cells, confirmed by western blot using di-phospho ERK1&2 antibody (Supplementary Figure S7). Second, 
we performed two additional sets of experiments to confirm the EGF-mediated PKA activation in HeLa cells. In 
the former, a decrease of AKARdual mean fluorescence lifetime upon EGF treatment (Δ Lifetime of − 41 ± 9 ps 
at t = 20 min) symptomatic of an increase of PKA activity which was unaffected by U0126 treatment (mean 
Δ Lifetime from t = 42 min to t = 60 min of − 53 ± 3 ps) was observed in HeLa cells (Fig. 4). This decrease has 
to be compared to DMSO control where no significant change was observed in the same experimental regime 
(black curve). Note that at our excitation regime, no photobleaching was observed for AKARdual intensity (Fig. 4B 
bottom). In the latter, using the original AKAR4 (Cerulean/cpVenus) biosensor29 and ratiometric FRET measure-
ments we confirmed the EGF-mediated PKA activation in HeLa cells (Supplementary Figure S8). One could ask 
how this EGF-mediated PKA activation might shape ERK1&2 kinase activity in HeLa cells.
cAMP inhibition of EGF-mediated ERK1&2 activity is uncoupled from PKA activity level. Taking 
into consideration that different modes of cAMP and PKA activation can lead to a contradictory effect on 
ERK1&2, we finalized our study by exploring the effect of cAMP- versus EGF-induced PKA activation on 
ERK1&2 activity. Using HeLa cells co-expressing AKARdual and EKARdual, we simultaneously monitored PKA 
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Figure 3. Validation of AKARdual and EKARdual using single wavelength excitation dual colour FLIM 
reveals an EGF-mediated PKA activation in HeLa cells. (A) Illustrations represent AKARdual (up) and 
EKARdual (down) biosensors. Biosensors were re-engineered with the following pairs of fluorescent protein: 
mTFP1/ShadowG for EKARdual and LSSmOrange/mKate2 for AKARdual. Substrates of ERK1&2 or PKA kinases, 
specific recognition domains of the phosphorylated substrates, and the ERK1&2 docking site in EKARdual were 
unmodified and so kept identical to the respective original biosensors. For both sets of treatment, representative 
fluorescence intensity (most left images) and associated 3D Δ Lifetime images are shown for each channel: cyan 
for EKARdual (top row) and orange for AKARdual (bottom row). (B) and (D) baseline (left column), activation 
by Fsk or EGF (middle column) and H89 or U0126 inhibition (right column), respectively. Graphs represent 
mean EKARdual and AKARdual Δ Lifetime along time (60 min) during baseline (mean Δ Lifetime from t = 0 min 
to t = 10 min of 0 ± 2 ps for both EKARdual and AKARdual in C and E), upon activation by Fsk or EGF (mean 
Δ Lifetime from t = 12 min to t = 40 min of − 9 ± 2 ps for EKARdual and − 42 ± 1 ps for AKARdual in C and of 
− 49 ± 2 ps for EKARdual and − 46 ± 2 ps for AKARdual in E), and H89 or U0126 inhibition (mean Δ Lifetime 
from t = 42 min to t = 60 min of − 6 ± 3 ps for EKARdual and − 20 ± 3 ps for AKARdual in C and of − 10 ± 3 ps 
for EKARdual and − 44 ± 3 ps for AKARdual in E) phases. Graphs, underneath mean EKARdual and AKARdual 
Δ Lifetime graphs, represent fluorescence intensity along time (60 min) during baseline, upon activation by 
Fsk or EGF and H89 or U0126 inhibition phases. Fsk/H89 (n = 20), EGF/U0126 (n = 26). [Fsk] = 12.5 μ M, 
[H89] = 20 μ M, [EGF] = 100 ng/ml, and [U0126] = 20 μ M. Fluorescence lifetime curves were calculated as a 
mean ± SEMs. (n) indicates the number of cells from at least 3 independent experiments. Scale bar = 10 μ m.
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and ERK1/2 activities by single excitation wavelength dual colour FLIM, upon co-activation and co-inhibition 
of both signalling pathways (Fig. 5). EGF-mediated ERK1&2 and forskolin-mediated-cAMP-dependent PKA 
activations resulted in an almost concomitant activation of both PKA and ERK1&2, peaking around 8 minutes 
after stimulation (Δ Lifetime of − 58 ± 8 ps for EKARdual and − 71 ± 6 ps for AKARdual at t = 18 min). However, the 
ERK1&2 activation profile upon combined forskolin and EGF stimulations was somewhat different from that of 
EGF treatment alone (Fig. 3B and Supplementary Figure S4B). Indeed, it resulted in a more transient ERK1&2 
activation (Δ Lifetime of − 34 ± 12 ps at t = 30 min), while PKA activity remained relatively stable until H89 inhib-
itor treatment (Δ Lifetime of − 62 ± 9 ps at t = 30 min), as previously shown (Fig. 3A and Supplementary Figure 
S4A). While dual pathway inhibitions produced the symptomatic decrease in both PKA and ERK1&2 kinase 
activities, we note that in these experimental conditions the inhibition reverted both kinase activity levels beyond 
baseline levels (Δ Lifetime of 51 ± 20 ps for AKARdual and Δ Lifetime of 57 ± 23 ps for EKARdual at t = 60 min). We 
Figure 4. EGF-mediated PKA activation in HeLa cells confirmed on dual colour FLIM using AKARdual.  
(A) Representative fluorescence intensity (most left image) and associated 3D Δ Lifetime images are shown for the 
orange channel. AKARdual (n = 19): baseline (left), activation by EGF (middle) and U0126 inhibition (right).  
(B) The orange graph represents mean AKARdual Δ Lifetime along time (60 min) during baseline (mean ΔLifetime 
from t = 0 min to t = 10 min of 0 ± 3 ps), upon activation by EGF (Δ Lifetime of − 41 ± 9 ps at t = 20 min), 
and U0126 inhibition (mean Δ Lifetime from t = 42 min to t = 60 min of − 53 ± 3 ps) phases. The grey graph 
represents DMSO control. Graph, below of mean AKARdual Δ Lifetime graph, represents fluorescence intensity 
along time (60 min) during baseline, upon activation by EGF and U0126 inhibition phases. [DMSO] = 1/1000, 
[EGF] = 100 ng/ml, and [U0126] = 20 μ M. Fluorescence lifetime curve was calculated as a mean ± SEMs.  
(n) indicates the number of cells from at least 3 independent experiments. Scale bar = 10 μ m.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:41026 | DOI: 10.1038/srep41026
show a cAMP-mediated reversal on EGF-mediated ERK1&2 activity increase. Compelling evidences demon-
strated that the ERK1&2 cascade is regulated by cAMP/PKA pathway (for review10). This crosstalk was reported 
to modulate the duration and the strength of ERK1/2 activity35, mainly in a Raf-isoform-dependent manner11.
To overcome problems with competition or synergistic effects with activator and inhibitors, we proceeded 
with a different treatment protocol. EGF and then Forskolin/IBMX stimulations, followed by U0126 and then 
H89 inhibitions were successively applied (Fig. 6). EGF stimulation resulted in concomitant ERK1&2 and PKA 
activations (Δ Lifetime of − 43 ± 4 ps for AKARdual and − 56 ± 5 ps for EKARdual at t = 16 min) as previously 
measured. The subsequent Forskolin/IBMX treatment potentiated PKA activation (Δ Lifetime of − 69 ± 8 ps for 
AKARdual at t = 30 min) while reverting ERK activation (Δ Lifetime of 33 ± 9 ps for EKARdual at t = 30 min) in 
a way comparable to what was initially observed with the combined EGF/Forskolin stimulation (Fig. 5). Upon 
Figure 5. Forskolin treatment negatively impacts EGF-mediated ERK1&2 activation in HeLa cells.  
(A) Representative fluorescence intensity (most left images) and associated 3D Δ Lifetime images are shown  
for each channel: cyan for EKARdual (top row) and orange for AKARdual (bottom row): Baseline (left column), 
co-activation by Fsk and EGF (middle column), and H89 and U0126 inhibition (right column), respectively.  
(B) Graph represents mean EKARdual (blue) and AKARdual (orange) Δ Lifetime along time (60 min) during baseline 
(mean Δ Lifetime from t = 0 min to t = 10 min of 0 ± 3 ps for EKARdual and 0 ± 3 ps for AKARdual), upon  
co-activation by Fsk and EGF (peaking at Δ Lifetime of − 58 ± 7 ps for EKARdual and − 70 ± 6 ps for AKARdual 
at t = 18 min), and H89 and U0126 inhibition (Δ Lifetime of + 45 ± 20 ps for EKARdual and + 15 ± 24 ps 
for AKARdual at t = 44 min) phases; n = 26. [Fsk] = 12.5 μ M, [H89] = 20 μ M, [EGF] = 100 ng/ml, and 
[U0126] = 20 μ M. Fluorescence lifetime curves were calculated as a mean ± SEMs. (n) indicates the number of 
cells from at least 3 independent experiments. Scale bar = 10 μ m.
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U0126 treatment, ERK1&2 activity returned to basal level (Δ Lifetime of − 4 ± 8 ps at t = 38 min), without affect-
ing PKA activity (Δ Lifetime of − 63 ± 8 ps at t = 38 min). Only addition of H89, precipitated PKA activity back 
to basal level (Δ Lifetime of − 15 ± 10 ps at t = 64 min) and further decreased ERK1&2 activity levels (Δ Lifetime 
of 36 ± 13 ps at t = 64 min) due to H89 off target effects. This came as no surprise due to the known multifac-
eted pharmacology of H89, which has also been reported to inhibit other kinases including the mitogen acti-
vated protein kinase kinase-1 (MEK1)44. The simultaneous recording of PKA and ERK1&2 kinase activities 
revealed concomitant EGF-mediated activations of both kinases in HeLa cells. In this situation the subsequent 
Forskolin-induced cAMP release reversed the transient increase of EGF-mediated ERK1&2 kinase activity while 
reinforcing PKA activation.
This last set of experiments confirmed that we were able to monitor two kinases activity profiles modu-
lated by different stimulus, with no lag time or spatial distribution discrimination. Importantly, if the spectral 
bleed-through had been detrimental, we would never have been able to measure such independent variations of 
PKA and ERK1&2 signalling pathways. Overall, we confirm that our methodology is well adapted for multiplex-
ing of genetically encoded FRET biosensor.
Discussion
Here we report on the validation of a multiplexed approach to follow two genetically encoded FRET-based kinase 
activity reporters at the same time in the same sample and in the same cellular compartment. Commonly, FRET 
is measured by the fluorescence intensity ratio of the acceptor to the donor. In that case, whatever the two flu-
orescent protein FRET pairs chosen, CFP/YFP and mOrange/mCherry21, mTFP1/mCitrine and mAmetrine/
tdTomato22,23, mTagBFP/sfGFP and mVenus/mKok24, the multiplexed approach suffers from two limitations: 
(i) a spectral bleed-through of the first acceptor in the second donor emission band that depends directly on the 
respective quantities of the two biosensors and (ii) the multiple excitation wavelength which requires sequential 
acquisition, and thus is not adequate to follow fast signal dynamics or signal changes in highly motile sample.
To overcome the first limitation, a meroCBD biosensor modified with a far red organic fluorophore (Alexa750) 
was used for probing Cdc42 simultaneously with a genetically encoded CFP/YFP FRET-based biosensor for Rho 
A45. This approach prevents spectral bleed-through but cannot be generalized to all genetically encoded FRET 
biosensors where organic fluorophores are not easily utilised to replace fluorescent proteins. Recently, an elegant 
method based on linear unmixing of 3D excitation/emission fingerprints applied to three biosensors simulta-
neously was published46. This type of approach based on image calculation is often limited by the different bio-
sensors expression level and a poor signal to noise ratio after complex image corrections. In our approach, we 
use FLIM instead of ratio imaging to measure FRET. When FRET occurs, donor fluorescence lifetime decreases. 
The method requires measurement of the donor fluorescence only and is independent of emission from the 
acceptor. Thus we can use a dim-fluorescent acceptor such as ShadowG to overcome the problems of spectral 
bleed-through. Other multiplex studies were carried out utilizing FLIM. By using CFP and YFP as donor and the 
same red acceptor (tHcRed), FLIM of CFP and YFP donor allows distinguishing the two different FRET signals47. 
Figure 6. Increasing cAMP levels reverts EGF-mediated ERK1&2 activation while reinforcing PKA 
activity. ERK1&2 and PKA kinase activity profiles measured in HeLa cells co-expressing EKARdual and 
AKARdual treated by indicated activators and inhibitors, using single wavelength excitation dual colour FLIM 
system. Graph represents mean EKARdual (blue) and AKARdual) Δ Lifetime along time (78 min) during baseline 
(Δ Lifetime of 0 ± 2 ps for EKARdual and 0 ± 2 ps for AKARdual over 10 min), upon activation EGF (peaking 
of Δ Lifetime of − 56 ± 5 ps for EKARdual and − 43 ± 4 ps for AKARdual at t = 16 min) followed by Fsk/IBMX 
treatment (Δ Lifetime of − 33 ± 9 ps for EKARdual and − 69 ± 8 ps for AKARdual at t = 30 min) and U0126  
(Δ Lifetime of − 4 ± 8 ps for EKARdual and − 63 ± 8 ps for AKARdual from inhibition to t = 38 min) followed 
by H89 inhibition phases (Δ Lifetime of 35 ± 13 ps for EKARdual and − 15 ± 10 ps for AKARdual at t = 64 min); 
n = 19. [Fsk] = 12.5 μ M, [H89] = 20 μ M, [EGF] = 100 ng/ml, and [U0126] = 20 μ M. Fluorescence lifetime curves 
were calculated as a mean ± SEMs. (n) indicates the number of cells from at least 3 independent experiments.
www.nature.com/scientificreports/
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Combination of FLIM-FRET of a red-shifted TagRFP/mPlum pair with ratio imaging of a CFP/Venus pair allows 
maximal spectral separation while at the same time overcoming the low quantum yield of the far-red acceptor 
mPlum48. Actually, in these two last examples the spectral bleed-through was alleviated but not the limitation 
associated with the multiple excitations.
To overcome the second limitation, the two FRET pairs CFP/YFP and Sapphire/RFP in combination with 
a single violet excitation were used49 resulting in no lag time in biochemical activity recording. However, the 
spectral bleed-through and excitation crosstalk once again necessitates linear unmixing. Another interesting 
approach for multiplexing two FRET activities was developed by Schervakova and co-workers, where a large 
stokes shift orange fluorescent protein (LSSmOrange) was used. The authors combined a CFP-YFP together with 
LSSmOrange-mKate2 biosensors enabling imaging of apoptotic activity and calcium fluctuations in real time 
using intensity-based methods25. Note that in this work, apoptotic activity was monitored by cleaved FRET bio-
sensor giving a 0–1 answer different to conformational FRET biosensor where quantification is required. In our 
method, we also take advantage of a CFP like protein together with LSSmOrange to be able to use a single 440 nm 
excitation. Moreover, because we combine this with dual colour FLIM approach, we are also able to significantly 
reduce the EYFP like spectral bleed-through in LSSmOrange channel by using a dim-fluorescent acceptor such 
as ShadowG. Our approach overcomes both limitations in the multiplexing experiments using one excitation 
wavelength for two FRET fluorescent protein pairs, and reducing the spectral bleed-through between biosensors 
by using ShadowG as an acceptor for mTFP1.
In a second stage, we wanted to assess whether our methodology would be a reliable one towards multipar-
ametric biosensing. Because the study of the intricate relationship between cAMP/PKA and MAPK/ERK1&2 
signal transduction pathways regularly provides new mechanistic insights15,18,35, we opted for it as a structured 
and defined playground for application purposes.
Our results using EKARdual and AKARdual clearly reflect the complexity of cAMP/PKA-MAPK/ERK1&2 inter-
connections. This crosstalk is usually presented from the following perspective: how does cAMP/PKA modulate 
MAPK/ERK1&2 activity11? Aside from hormone receptors signalling effects on PKA, GF-induced PKA activation 
was also long reported50, with a keen interest for PKA implication in tumour biology51.
Our first observation, using single excitation wavelength dual colour FLIM with specifically optimized PKA 
and ERK1&2 kinase activity reporters, is an EGF-mediated PKA activation concomitant to that of ERK1&2 in the 
cervical cancer HeLa cell line. The reported PKA-RI subunit preponderance in cancer cells and its direct inter-
action with the EGFR via the Gbr2 adaptor protein51, together with recent evidences of PKA-Cα subunit phos-
phorylation by RTKs42 can explain our observation. In addition, scaffolds proteins such as AKAP-Lbc and KSR-1, 
that were reported to favour discrete localizations of both PKA and ERK1&2 generating pockets of concentrated 
enzyme activities, were shown to provide platforms for mitogenic signal amplification15. Actually, compartmen-
talized GF-induced PKA activation modulating the features of ERK1&2 kinase activity was recently illustrated 
in an elegant study from Zhang’s group35. While monitoring of compartmentalized PKA and ERK1&2 enzyme 
activities was beyond the scope of our study, it could now be performed in a multiplex manner thus maximizing 
crosstalk relevance at the single living cell level.
Raf isoforms expression levels were shown to be implicated in the various responses exerted by cAMP/PKA on 
MAPK/ERK1&2 signalling52. Differences in ERK1&2 kinase activity mainly result from the differential activation 
of either Ras/C-Raf-1/MEK/ERK or Rap1/B-Raf/MEK/ERK11. Activation of the exchange protein directly acti-
vated by cAMP (Epac) upon cAMP increasing levels triggers activation of Rap1 and sustained activation of B-Raf/
MEK/ERK pathway53. By contrast, cAMP-mediated PKA activation is generally known to directly inhibit C-Raf-1, 
mediated by AKAP preventing over-activation of cAMP-mediated ERK1&2 pathway. Our second observation 
would be in line with the latter since forskolin-induced cAMP levels increase reverted activation of EGF-mediated 
ERK1&2 while reinforcing PKA activity. However, cAMP was reported to either inhibit C-Raf-1 or activate B-Raf. 
Therefore, cells expressing low B-Raf level will preferentially impair mitogenic signals in response to cAMP 
release. Actually, B-Raf kinase activity level has been found to be low in HeLa cells relative to A-Raf, while being 
intermediate for C-Raf-154. Thus, in Hela cells, MEK/ERK1&2 signalling upon a mitogenic stimulation is mainly 
mediated by A-Raf. Actually, A-Raf triggers a MEK-1 dependent ERK1&2 activation upon EGF-treatment55 with 
a known ERK1&2 nuclear translocation. Using the recently published ERK2-LOC translocation reporter56 and a 
similar ERK1-LOC would be an elegant way to control whether the observed EGF-mediated ERK1&2 activation is 
A-Raf/MEK1 dependent. Although cAMP/PKA-mediated A-Raf regulation remains unclear, it is generally agreed 
that the target of cAMP is C-Raf-12. How and if PKA activity can contribute to both EGF-mediated ERK1&2 acti-
vation and Forskolin-induced reversal of EGF-mediated ERK1&2 kinase inhibition remains unanswered in this 
cellular context. Other possible explanations arise from recent studies involving a PDE isoforms (PDE8A), which 
associates with C-Raf to protect it from inhibitory phosphorylation by PKA18. This actually enhances C-Raf to 
stimulate ERK1&2 cascade. Another connection with MAPK/ERK1&2 at the PDEs level should be mentioned. 
Indeed, ERK2 was reported to phosphorylate the C-terminal catalytic domain of several PDEs17. Taken together 
one might speculate whether EGF- and cAMP-mediated signals exert different modus of active PKA.
Our methodology provides evidence of the relevance of a multidimensional kinase activity profiling in living 
cells. Indeed, we have depicted here a process where simultaneously ERK1&2 and PKA kinases activities record-
ings in HeLa cells were successfully carried out. Results obtained at the single living cell level, within the same cell, 
and at the same time provide a glimpse of how cells integrate in real-time external signals upon dual signalling 
pathway engagement. In this study, we have used FRET biosensor diffusing all over the cell. The sub-cellular 
localization of the activation is not easy to measure since the diffusion of the probe is too fast compared to the 
speed of measurement. A promising solution would be to localize the kinase biosensors with targeting signal 
peptides29. Questions raised from such multidimensional biochemical activities profiling pave the way for future 
experiments aiming at untangling cellular signalling crosstalk.
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As a perspective, since FLIM is adequate for quantitative intermolecular FRET57, our approach is easily trans-
posable to study protein-protein interactions. Additionally, the possibility to expand our method to three biosen-
sors could be achieved by using a non-fluorescent acceptor for LSSmOrange and a third large stoke shift donor 
such as LSSmKate58 in combination with an infra-red acceptor such as IRFP67059.
Methods
Reagents. Human epithelial growth factor (EGF, #E9644), MEK inhibitor (U0126, #U120) and dimethylsul-
foxide (DMSO, #D8418) were purchased from Sigma Aldrich. Forskoline (Fsk, #1099), an adenylate cyclase acti-
vator responsible for cAMP production, PKA inhibitor (H89 dihydrochloride, #2910) and phosphodiesterase 
inhibitor (IBMX, #2845) were purchased from Tocris.
Plasmids. GFP-sREACh (mGFP-10-sREACh-N3 from Dr Ryohei Yasuda, Addgene plasmid #21947) and 
mTFP1 vectors were digested with NheI and BamHI. mTFP1 fragment was inserted into the corresponding restric-
tion sites in the GFP-sREACh (− /sREACh) vector to create the new vector mTFP-sREACh. EGFP-Shadow (was 
gift from Dr Murakoshi, National Institute for Physiological Sciences, Japan) and mTFP1-sREACh vectors were 
digested with BamHI and NotI. ShadowG fragment was inserted into the corresponding restriction sites in the 
mTF1-sREACh (mTFP1/-) vector to create the new vector mTFP1-ShadowG. LSSmOrange (pLSSmOrange-C1 
from Dr Vladislav Verkhusha, Addgene #37130 plasmid) was inserted in EGFP-C3 vector by digestion with AgeI 
and BsrGI to create a new vector LSSmOrange-C3. LSSmOrange-C3 generated is used to insert LSSmOrange 
in mKate2-N plasmid (from Dr Sergi Padilla-Parra) by digestion with NdeI and BamHI to create a new vec-
tor LSSmOrange-mKate2. FRET biosensor plasmid EKAR2G (monomeric Teal Fluorescent Protein (mTFP1)/
Venus, Addgene plasmid #39813) was a gift from Dr. Olivier Pertz (Department of Biomedicine, University of 
Basel, Switzerland). AKAR4 plasmid was kindly provided by Dr. Jin Zhang (Department of Pharmacology and 
Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, USA). EKAR2G (mTFP1/Venus) 
vector was digested with NotI and KpnI to release the Venus insert generating the EKAR2G (mTFP1/-) vector. 
ShadowG plasmid was a gift from Dr Murakoshi (National Institute for Physiological Sciences, Japan). ShadowG 
coding sequence was amplified from the ShadowG plasmid using the forward primer ShadowG.NotI (NotI site 
underlined) and the reverse primer ShadowG.KpnI (KpnI site underlined). ShadowG coding sequence was then 
inserted into the corresponding restriction sites in the EKAR2G (mTFP1/-) backbone in frame with EKAR2G 
Molecular Recognition Element (MRE) and the upstream mTFP1 fluorescent protein to create the new expres-
sion vector EKARdual (mTFP1/ShadowG). AKAR4 (Cerulean/cpVenus) vector was digested to remove sequen-
tially Cerulean (BamHI and SphI) and cpVenus (SacI and EcoRI) inserts. LSSmOrange and mKate2 fluorescent 
proteins were then amplified from pLSSmOrange-C1 (from Dr Vladislav Verkhusha, Addgene plasmid #37131) 
and pmKate2-N1 (from Dr Sergi Padilla-Parra) respectively using the following primer pairs (forward/reverse): 
LSSmOrange.BamHI-F/ LSSmOrange.SphI-R and LSS-mKate2.SacI-F/mKate2.EcoRI-R. LSSmOrange and 
mKate2 PCR products were subsequently sub-cloned into the corresponding restriction sites in the AKAR4 
(−/cpVenus) and AKAR4 (LSSmOrange/-) backbones respectively in frame with the AKAR4 MRE to create 
the new expression vector AKAR4dual (LSSmOrange/mKate2). All resulting constructs were verified by restric-
tion digestion onto agarose gel electrophoresis and then validated by sequencing (VIB for AKAR4 derivatives 
and IGDR for EKAR2G derivatives). All enzymes and buffers were purchased from New England Biolabs. 
Oligonucleotides were synthesized by Integrated DNA Technologies (Belgium) and Sigma-Aldrich (France) 
AKAR4 and EKAR2G, respectively. DNA fragments were all purified on Qiagen plasmid purification columns 
(#28106, #28706 and #27106, Qiagen).
Cell Culture and Transfection. HeLa cells were purchased from the European Collection of Cell Cultures 
(UK) and U2OS cells were a gift from Dr Gyula Timinszky (LMU, Munchen, Germany). HeLa and U2OS cells 
were maintained at 37 °C under 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM, #E15-009, PAA) sup-
plemented with 10% fetal bovine serum (FBS, #A15-101, PAA), 1% penicillin/streptomycin (P/S, #15140-122, 
Gibco, Life Technologies) and 1% L-Glutamine (Glu, #25030024, Gibco, Life Technologies). For live cell imaging, 
cells were seeded on Lab-Tek 4 wells (#055078, Dominique Dutscher) at 60% confluence 24 h before transfection 
on day 1. On day 2, transfections were carried out using JetPrime reagent (#114-15, Polyplus) according to the 
manufacturer’s instructions. After 4 h of incubation with the transfection mixture, medium was replaced by 400 μ l 
per well of culture medium composed of FluoroBrite phenol red-free medium (#A18967-01, Life Technologies) 
containing 0.1% FBS for overnight starvation. For experiment relating to Fig. 2, U2OS cells were transfected with 
0.5 μ g/well of LSSmOragne-mKate2 plasmid, and 0.25, 0.5, 0.75, and 1 μ g/well of the different mTFP1-Yellow 
plasmids, in order to generate cells with an array of tandem constructs expression levels.
Imaging for biosensing experiments. For cell treatments, activators or inhibitors were diluted in 
pre-heated FluoroBrite medium in a final volume of 100 μ l and were carefully added to the well. Concentration 
used: [DMSO] = 1/1000, [Fsk] = 12.5 μ M, [IBMX] = 75 μ M, [H89] = 20 μ M, [EGF] = 100 ng/ml, and 
[U0126] = 20 μ M. Standard protocol for biosensing experiment was as follows. Cells were positioned on the 
microscope stage 30 min before the beginning of each experiment. The first 10 minutes of imaging where cells 
were untreated provided basal kinases activity levels (correspond to baseline phase). Upon signalling pathways 
activation, images were acquired for a 30 minutes period, which was prolonged of 20 minutes upon signalling 
inhibitor. Images were acquired at 2 minute intervals.
FRET imaging. FLIM-FRET experiments. For the characterization of LSSmOrange fluorescence lifetime, 
we used a time correlated single photon counting (TCSPC) system. This system, a confocal microscope Leica SP8 
(Manheim, Germany), is equipped with single molecule detection (SMD) module based on Picoquant hardware 
(Berlin, Germany). Briefly, a 440 nm diode pulsed laser at 40 MHz repetition rate is fiber-coupled to the confocal 
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head of an inverted microscope with a 63× or 40× oil immersion objective (NA = 1.4 or 1.30 respectively) and 
the fluorescence emission after passing through pinhole set at 1 Airy unit is directed to the external port con-
nected to a two colour coupling module with a dichroic mirror of 505 nm splits the fluorescence in two channels 
with 480/30 nm and 579/34 nm band pass filters. Two optical fibres are used to couple two single-photon ava-
lanche diode (SPAD) detectors; photon counting detector (MPD from PDM) module for the cyan channel and a 
red sensitive SPAD (TauSPAD from Picoquant) for the orange channel used as Single Photon Counting detectors. 
A Picoharp 300 is used for Time-Correlation and for image reconstruction using scanning signals to recover 
FLIM images (time-tagged time resolved (TTTR) method). Lifetime value from cell to cell was determined by 
fitting the fluorescence decay of the whole cell Region Of Interest with a single exponential model.
For single excitation wavelength dual colour FLIM system we used our FastFLIM system. This FLIM sys-
tem equipped with a pulsed white light laser tuned at 80 Mhz coupled to a live cell fluorescence microscope 
and dual colour emission coupled to a FLIM detection previously described in ref. 30. After wavelength selec-
tion of the supercontinuum at 440 nm (with about 10 nm narrow band of excitation), the laser is coupled to a 
multifocal spinning disk CSUX1 (Yokogawa, Japan) and cells were imaged using a 63× or 20× oil immersion 
objective (NA = 1.4 or 0.70 respectively). At the emission side, a Dual View (DV2 multichannel imaging system, 
Photometrics, USA) was used to split the field of view of the camera in two colours, using a dichroic mirror at 
505 nm splitting the fluorescence emission in two channels: 480/30 nm and 579/34 nm band pass filters. Then the 
fluorescence image was directed to a High Rate Intensifier (Picostar, LaVision, Germany) coupled to a charged 
coupled device (CCD) camera (CoolSNAP HQ2, Photometrics, USA). Five time-gated images of 2 ns gate width 
were sequentially acquired (using 100 to 300 ms exposure time depending on the intensity of the sample) with 
different delays relative to the pulsed laser (from 0 to 8 ns). The time-gated stack of 5 images was then used for 
direct calculation of mean fluorescence lifetime in a pixel by pixel basis60.
Ratiometric FRET experiments. For sensitized emission measurements of AKAR4 biosensor in HeLa cells 
wide-field images were captured with a Nikon TiE inverted microscope with a 20 × 0.5NA objective and a 
DS-Qi2 CMOS camera (Nikon, Japan). Images were acquired at intervals of 2 min with the Nikon NIS-Elements 
acquisition software using JOBS module (Nikon, Japan). A Lumencor Spectra X LED Light Engine (Lumencor, 
Beaverton, OR, USA) was used as excitation light source to reduce phototoxicity. Ratio imaging used a 440/30 nm 
excitation filter, a t440/510/575rpc multi-band dichroic mirror, and two emission filters (ET480/40 M (cyan flu-
orescent protein: CFP) and AT545/30 M (FRET)). Lumencor provided excitation filters, and all dichroic mirrors 
and emission filters were obtained from Chroma Technology (Brattleboro, VT, USA). An automated emission 
filter wheel Lambda 10-B Smart Shutter (Sutter Instrument, Novato, CA, USA) was used. The F480/F545 emis-
sion ratio, indicative of biosensor activation, calculated for each pixel on the whole image, was performed with 
custom routines written in IGOR Pro environment (Wavemetrics, Lake Oswego, OR, USA). Normalized F480/
F545 emission ratio values were then plotted in PrismV (GraphPad software, La Jolla, CA, USA) and displayed in 
two ways: cell trace for each individual cell (grey) overlaid with the population mean in red and the 25th and 75th 
percentile values in blue.
Data analysis. For the TCSPC analysis, Symphotime software (Picoquant, Berlin, Germany) was used to 
analyze our imaging data. The channel 1 (cyan channel) or 2 (orange channel) was selected. Regions of Interest on 
different cells were fitted using a single or a double-exponential decay.
The fastFLIM system produces an intensity image from the first time-gated image and a lifetime image from 
the calculation of the direct first order temporal mean of the recorded decay (< τ > = Σ ti Ii/Σ Ii where ti and Ii 
correspond to the correlated time and the intensity of the time-gated channel I, respectively). Manual segmenta-
tion of the different cells was carried out to recover the mean lifetime at different time points of the experiments.
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